-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Drop in Short Interest
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Drop in Short Interest
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decrease of 27.5% from the October 15th total of 48,700 shares. Currently, 0.4% of the company's stock are short sold. Based on an average daily trading volume, of 31,100 shares, the days-to-cover ratio is currently 1.1 days.
Institutional Trading of Avalo Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Leo Brokerage LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter valued at $45,000. Assenagon Asset Management S.A. bought a new stake in Avalo Therapeutics during the third quarter valued at about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after buying an additional 327,241 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Avalo Therapeutics by 23.8% in the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Avalo Therapeutics during the 2nd quarter valued at about $506,000.
Get Avalo Therapeutics alerts:Avalo Therapeutics Stock Performance
NASDAQ:AVTX traded down $0.30 on Friday, hitting $5.80. The stock had a trading volume of 32,230 shares, compared to its average volume of 24,928. Avalo Therapeutics has a 52-week low of $2.42 and a 52-week high of $27.96. The company has a current ratio of 1.07, a quick ratio of 0.97 and a debt-to-equity ratio of 5.23. The business's 50-day simple moving average is $4.90 and its two-hundred day simple moving average is $5.19.
Analyst Ratings Changes
Separately, Oppenheimer reduced their target price on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday.Avalo Therapeutics Company Profile
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Featured Articles
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decrease of 27.5% from the October 15th total of 48,700 shares. Currently, 0.4% of the company's stock are short sold. Based on an average daily trading volume, of 31,100 shares, the days-to-cover ratio is currently 1.1 days.
阿瓦洛治療公司(納斯達克代碼:AVTX-GET評級)是10月份空頭股數使用量大幅下降的接受者。截至10月31日,空頭股數共有3.53萬股,比10月15日的4.87萬股減少了27.5%。目前,該公司0.4%的股票被賣空。以日均成交量31,100股計算,目前天數與回補比率為1.1天。
Institutional Trading of Avalo Therapeutics
Avalo治療公司的機構交易
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Leo Brokerage LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter valued at $45,000. Assenagon Asset Management S.A. bought a new stake in Avalo Therapeutics during the third quarter valued at about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after buying an additional 327,241 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Avalo Therapeutics by 23.8% in the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Avalo Therapeutics during the 2nd quarter valued at about $506,000.
一些對衝基金和其他機構投資者最近增持或減持了該業務的股份。Leo Brokerage LLC在第一季度購買了Avalo治療公司的新股份,價值4.5萬美元。Assenagon Asset Management S.A.在第三季度購買了Avalo Treeutics的新股份,價值約5.2萬美元。復興技術公司在第一季度將其在阿瓦洛治療公司的地位增加了819.1%。復興科技有限責任公司現在持有該公司367,193股股票,價值266,000美元,上個季度又購買了327,241股。高盛股份有限公司在第二季度增持了阿瓦洛治療公司的股份23.8%。高盛股份有限公司在此期間增持了124,769股,目前持有649,653股該公司股票,價值324,000美元。最後,Millennium Management LLC在第二季度購買了價值約506,000美元的Avalo治療公司的新股票頭寸。
Avalo Therapeutics Stock Performance
Avalo治療公司股票表現
NASDAQ:AVTX traded down $0.30 on Friday, hitting $5.80. The stock had a trading volume of 32,230 shares, compared to its average volume of 24,928. Avalo Therapeutics has a 52-week low of $2.42 and a 52-week high of $27.96. The company has a current ratio of 1.07, a quick ratio of 0.97 and a debt-to-equity ratio of 5.23. The business's 50-day simple moving average is $4.90 and its two-hundred day simple moving average is $5.19.
納斯達克:AVTX週五下跌0.3美元,觸及5.8美元。該股成交量為32,230股,而其平均成交量為24,928股。Avalo Treateutics的52周低點為2.42美元,52周高位為27.96美元。該公司的流動比率為1.07,速動比率為0.97,債務權益比率為5.23。該業務的50日簡單移動均線切入位為4.90美元,200日簡單移動均線切入位為5.19美元。
Analyst Ratings Changes
分析師評級發生變化
Avalo Therapeutics Company Profile
Avalo治療公司簡介
(Get Rating)
(獲取評級)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家臨牀階段的精密藥物公司,為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向療法。該公司開發了AVTX-002,這是一種完全人類抗光的單抗,正在進行第二階段臨牀試驗,用於治療非嗜酸性哮喘以及炎症性腸道疾病,包括中到重度克羅恩病和潰瘍性結腸炎;以及第三階段臨牀試驗,用於治療新冠肺炎急性呼吸窘迫綜合徵。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免費獲取StockNews.com關於Avalo治療公司(AVTX)的研究報告
- MarketBeat:回顧中的一週11/7-11/11
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎?
- 六面旗幟是一種你不想被困住的旅程
- Hanesbrand可能發出零售類股本週表現不佳的信號
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avalo治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧